Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

被引：0

作者：

Roch Houot

Guillaume Cartron

Fontanet Bijou

Sophie de Guibert

Gilles A. Salles

Christophe Fruchart

Krimo Bouabdallah

Marie Maerevoet

Pierre Feugier

Steven Le Gouill

Hervé Tilly

Rene-Olivier Casasnovas

Cécile Moluçon-Chabrot

Eric Van Den Neste

Pierre Zachee

Marc Andre

Christophe Bonnet

Corinne Haioun

Achiel Van Hoof

Koen Van Eygen

Lysiane Molina

Emmanuelle Nicolas-Virelizier

Philippe Ruminy

Franck Morschhauser

机构：

[1] University Hospital of Rennes,Department of Clinical Hematology

[2] Inserm 0203,Department of Clinical Hematology

[3] University of Rennes,Department of Hematology

[4] University Hospital of Montpellier,undefined

[5] UMR CNRS 5235,undefined

[6] University of Montpellier,undefined

[7] French Blood Institute,undefined

[8] Department of Hematology,undefined

[9] Centre Hospitalier Lyon-Sud,undefined

[10] Institut d’Hématologie de Basse Normandie (IHBN),undefined

[11] CHU,undefined

[12] Haematology,undefined

[13] CHU de Bordeaux,undefined

[14] Hematology,undefined

[15] Institut Jules Bordet,undefined

[16] CHU et INSERM 954,undefined

[17] Nancy Université,undefined

[18] Nantes University Hospital and UMR892 INSERM,undefined

[19] Centre Henri Becquerel,undefined

[20] Inserm U918,undefined

[21] Université de Rouen,undefined

[22] IRIB,undefined

[23] Hematology,undefined

[24] University Hospital,undefined

[25] Hematology Department,undefined

[26] CHU Clermont Ferrand,undefined

[27] Department of Hematology,undefined

[28] Cliniques Universitaires Saint-Luc,undefined

[29] AZ GROENINGE,undefined

[30] Hematology Department,undefined

[31] CHU UCL NAMUR,undefined

[32] Clinical Hematology,undefined

[33] CHU University of Liège,undefined

[34] Hôpital Henri Mondor,undefined

[35] Unité Hémopathies Lymphoide,undefined

[36] General Hospital St-Jan,undefined

[37] ZNA Stuivenberg,undefined

[38] Hematology,undefined

[39] CHU de Grenoble,undefined

[40] Hematology Department,undefined

[41] Centre Léon Bérard,undefined

[42] Université de Lille/ hopital Claude Huriez,undefined

来源：

Leukemia | 2019年 / 33卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：776 / 780

页数：4

共 50 条

[21] COST-EFFECTIVENESS OF OBINUTUZUMAB PLUS BENDAMUSTINE AND FOLLOWED BY OBINUTUZUMAB MAINTENANCE THERAPY IN CHINESE PATIENTS WITH RELAPSE AND REFRACTORY FOLLICULAR LYMPHOMA
Ma, J.
Zhen, B.
Xia, Y.
Gong, Q.
Li, Y.
Chen, W.
[J]. VALUE IN HEALTH, 2022, 25 (12) : S84 - S84
[22] Study points to lenalidomide as a promising treatment for aggressive lymphoma
不详
[J]. FUTURE ONCOLOGY, 2010, 6 (07) : 1070 - 1070
[23] Study points to lenalidomide as a promising treatment for aggressive lymphoma
不详
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 993 - 993
[24] Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine A case report
Zhou, Zhencang
Wu, Pengqiang
Wang, Fujue
Tao, Huan
Chen, Yingying
Gao, Jie
Chen, Dengke
Jia, Yongqian
[J]. MEDICINE, 2022, 101 (09) : E28938
[25] SINGLE-AGENT LENALIDOMIDE FOR THE TREATMENT OF RELAPSED OR REFRACTORY AGGRESSIVE LYMPHOMA PATIENTS
Puccini, B.
Chitarrelli, I.
Antognoli, G.
Fabbri, A.
Rigacci, L.
Lenoci, M. P.
Lauria, F.
Bosi, A.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 288 - 288
[26] A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.
Fehniger, Todd A.
Larson, Sarah
Trinkaus, Kathryn
Siegel, Marilyn J.
Cashen, Amanda F.
Blum, Kristie A.
Fenske, Timothy S.
Hurd, David D.
Goy, Andre
DiPersio, John F.
Bartlett, Nancy L.
[J]. BLOOD, 2009, 114 (22) : 1422 - 1422
[27] A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma
Fehniger, Todd A.
Watkins, Marcus P.
Ezenwajiaku, Nkiruka
Wan, Fei
Hurd, David D.
Cashen, Amanda F.
Blum, Kristie A.
Goy, Andre
Fenske, Timothy S.
Wagner-Johnston, Nina D.
Carson, Kenneth
Siegel, Marilyn J.
Russler-Germain, David
Schneider, Stephanie E.
Mehta-Shah, Neha
Kahl, Brad
Bartlett, Nancy L.
[J]. HAEMATOLOGICA, 2024, 109 (03) : 953 - 957
[28] Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa
Houot, Roch
Soussain, Carole
Tilly, Herve
Haioun, Corinne
Thieblemont, Catherine
Casasnovas, Olivier
Bouabdallah, Krimo
Morschhauser, Franck
Le Gouill, Steven
Salles, Gilles A.
Marchand, Tony
Pangault, Celine
Laurent, Camille
Lamy, Thierry
[J]. BLOOD, 2015, 126 (23)
[29] Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA
Houot, R.
Soussain, C.
Tilly, H.
Haioun, C.
Thieblemont, C.
Casasnovas, O.
Bouabdallah, K.
Morschhauser, F.
Le Gouill, S.
Salles, G. A.
Hoang-Xuan, K.
Choquet, S.
Marchand, T.
Laurent, C.
Pangault, C.
Lamy, T.
[J]. ANNALS OF ONCOLOGY, 2016, 27 (07) : 1349 - 1350
[30] Preliminary results from a phase II study of lenalidomide monotherapy in Relapsed/Refractory aggressive non-Hodgkin's lymphoma.
Wiemik, Peter H.
Lossos, Izidore
Tuscano, Joseph
Justice, Glen
Vose, Julie M.
Pietronigro, Dennis
Takeshita, Kenichi
Ervin-Haynes, Annette
Zeldis, Jerome B.
Habermann, Thomas M.
[J]. BLOOD, 2006, 108 (11) : 160A - 161A

← 1 2 3 4 5 →